KL
KLRS.US Kalaris Therapeutics, Inc.
- Market cap
- USD 37.5M
- P/E
- -
- P/B
- 0.79x
- ROE
- -93.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KLRS.US undervalued?
Graham numberThe Graham number of Kalaris Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kalaris Therapeutics, Inc. fundamental analysis
No fundamental analysis for Kalaris Therapeutics, Inc. yet.
Kalaris Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly know…
Full company profileKalaris Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kalaris Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.14M | 165K | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -73.0K | -1.12M | - | - | - | -13.0K | - |
| Operating Income | -3.60M | -26.7M | -71.3M | -170M | -14.0M | -13.5M | -55.3M | -46.2M | -48.0M |
| EBITDA | -2.43M | -23.8M | -69.7M | -170M | -15.3M | -14.0M | -58.8M | -42.0M | -46.7M |
| Net Income | -2.43M | -23.8M | -69.8M | -172M | -15.5M | -14.7M | -58.8M | -43.4M | -44.5M |
| EPS | -0.86 | -8.42 | -60 | -63 | -4.65 | -3.25 | -12 | -2.85 | -1.87 |
| Balance Sheet | |||||||||
| Total Assets | 25.3M | 139M | 371M | 287M | 3.90M | 3.33M | 119M | 122M | 89.0M |
| Total Liabilities | 3.74M | 17.8M | 17.8M | 61.3M | 34.2M | 48.4M | 5.24M | 42.9M | 41.6M |
| Shareholders' Equity | 21.6M | 122M | 353M | 225M | -30.3M | -45.0M | 113M | 78.8M | 47.4M |
| Cash & Short-term Investments | 25.0M | 126M | 356M | 248M | 3.06M | 3.17M | 118M | 118M | 82.9M |
| Total Debt | - | 11.8M | 8.69M | 30.1M | 3.25M | - | - | 1.45M | 1.33M |
| Cash Flow | |||||||||
| Operating Cash Flow | 1.94M | -20.2M | -60.8M | -106M | -9.78M | -14.1M | -67.7M | -38.4M | -47.1M |
| Capital Expenditure | 0.00 | 339K | 235K | 26.0K | 0.00 | 0.00 | 0.00 | 200K | 0.00 |
| Free Cash Flow | 1.94M | -20.5M | -61.0M | -106M | -9.78M | -14.1M | -67.7M | -38.6M | -47.1M |
| Ratios | |||||||||
| ROE | -11.3% | -19.6% | -19.8% | -76.3% | - | - | -51.9% | -55.1% | -93.9% |
| ROA | -9.6% | -17.1% | -18.8% | -60.0% | -397.2% | -441.0% | -49.6% | -35.7% | -50.0% |
| Net Profit Margin | -214.1% | -14,447.9% | - | - | - | - | - | - | - |
| Debt to Equity | - | 0.10x | 0.02x | 0.13x | - | - | - | 0.02x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kalaris Therapeutics, Inc. dividends
Kalaris Therapeutics, Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 1:23 on Jan 16, 2025.
Who owns Kalaris Therapeutics, Inc.
- Insiders 9.27%
- Institutions 78.94%
- Public & others 11.79%
- Shares outstanding 23.8M
- Free float 5.90M
Top funds holding KLRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 255K | 1.07% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 27.6K | 0.12% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 24.9K | 0.10% | -57.54% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 22.5K | 0.09% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 17.9K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 17.3K | 0.07% | 0.00% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 8.62K | 0.04% | 0.00% | Aug 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 8.02K | 0.03% | -10.43% | Jun 2026 |
| Fidelity VIP Disciplined Small Cap Init | 7.81K | 0.03% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 6.00K | 0.03% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 3.30K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 3.30K | 0.01% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 2.75K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 2.61K | 0.01% | 0.00% | Oct 2026 |
| DFA US Core Equity Class F | 1.94K | 0.01% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 1.73K | 0.01% | 0.00% | Sep 2026 |
| Victory Extended Market Index | 984.00 | 0.00% | +8.01% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 725.00 | 0.00% | 0.00% | Sep 2026 |
| Dimensional Global Core Equity USD Acc | 638.00 | 0.00% | -0.31% | Sep 2026 |
| JHVIT Total Stock Market Index I | 541.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding KLRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 12.9M | 54.11% | -0.52% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.30M | 5.46% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 573K | 2.41% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 436K | 1.83% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 399K | 1.67% | +56.14% | Jun 2026 |
| Ikarian Capital, LLC | 360K | 1.51% | 0.00% | Jun 2026 |
| UBS Group AG | 262K | 1.10% | +4,138.86% | Jun 2026 |
| Renaissance Technologies Corp | 177K | 0.74% | +18.42% | Sep 2026 |
| Marshall Wace Asset Management Ltd | 139K | 0.58% | +105.07% | Jun 2026 |
| Geode Capital Management, LLC | 114K | 0.48% | +30.26% | Jun 2026 |
| Woodline Partners LP | 100K | 0.42% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 100K | 0.42% | 0.00% | Jun 2026 |
| WHI TRUST Co LLC | 97.5K | 0.41% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 95.8K | 0.40% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 92.3K | 0.39% | 0.00% | Jun 2026 |
| Verdad Advisers, LP | 80.3K | 0.34% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 72.3K | 0.30% | +88.62% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 66.2K | 0.28% | +80.24% | Jun 2026 |
| BlackRock Inc | 54.4K | 0.23% | +51.05% | Jun 2026 |
| FORTIS CAPITAL ADVISORS, LLC | 40.0K | 0.17% | 0.00% | Jun 2026 |
Kalaris Therapeutics, Inc. company profile
- Company name
- Kalaris Therapeutics, Inc.
- Ticker
- KLRS.US
- Exchange
- USA Stocks
- Listed since
- Jul 30, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- 400 Connell Drive, Berkeley Heights, NJ, United States, 07922
- Phone
- 650 249 2727
- Website
- kalaristx.com
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Kalaris Therapeutics, Inc. management
9- Mr. Andrew OxtobyPresident, CEO & Director · born 1974
- Dr. Srinivas Akkaraju M.D., Ph.D.Director & Co-Founder · born 1968
- Dr. Michael Philip Dybbs Ph.D.Co-Founder & Director · born 1975
- Dr. Napoleone Ferrara M.D.Independent Director & Co-Founder · born 1957
- Dr. Matthew Feinsod M.D.Chief Medical Officer · born 1971
- Ms. Liisa Ann Bayko M.B.A.CFO & Treasurer · born 1971
- Ms. Amy VandekopInterim Principal Accounting Officer & Corporate Controller · born 1989
- Ms. Kristine CurtissSenior Vice President of Clinical
- Dr. Jill E. Porter Ph.D.Senior Vice President of CMC